⌑ I · The MechanismWhat's actually known.
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a fragment of human gastric juice protein. It was first characterized in the early 1990s by Sikiric and colleagues, who proposed that the parent compound exerted gastric cytoprotective effects via a stable peptide fragment.[1]
In animal models, BPC-157 has been documented to upregulate growth factor signaling — VEGF, EGFR, and growth hormone receptor expression — at sites of injury. This may promote angiogenesis (new blood vessel formation) and collagen synthesis, the two limiting factors in soft-tissue healing. Animal studies have shown accelerated healing in models of Achilles tendon transection, ligament injury, muscle laceration, gastric ulcer, intestinal anastomosis, and various other tissue injuries.[1][2]
BPC-157 also appears to modulate the nitric oxide (NO) system and to interact with dopaminergic and serotonergic pathways in central nervous system models — effects that have generated interest in possible neuroprotective applications, though again primarily in animal data.[1]
The mechanism story is plausible and supported by repeated animal studies — many from the same research group. The translation from rodent models to human clinical outcomes is precisely where most pharmaceutical candidates fail. The absence of well-designed human RCTs after three decades of investigation is a meaningful signal that should temper the marketing enthusiasm around this compound.
⌑ II · The EvidenceWhat the research actually shows.
- Animal tendon healing. Krivic et al. (2008) and subsequent studies demonstrated accelerated Achilles tendon outgrowth and healing in rats receiving BPC-157.[3]
- Animal gastric ulcer healing. The original use case. Multiple Sikiric group studies confirm rapid mucosal healing in NSAID-induced and stress-induced gastric ulcer models.[1]
- Animal CNS protection. Animal models of traumatic brain injury, encephalopathy, and chemical toxicity show protective effects.[1]
- Human evidence. Almost none of clinical RCT quality. A single small open-label trial (Tkalcevic et al., 2007) on inflammatory bowel disease patients showed safety and modest symptomatic improvement, but the trial design does not support efficacy claims.[4]
- Safety in animal studies. No significant toxicity reported across hundreds of animal studies at doses far exceeding typical human use. Pharmacokinetics, immunogenicity, and long-term human safety remain inadequately characterized.[1]
Despite widespread marketing, BPC-157 has no FDA approval, no published large-scale human RCT, and no established long-term safety profile in humans. The compounds sold through "research peptide" channels are not regulated by the FDA for purity, potency, or sterility. The 2022 WADA prohibited substance list now includes BPC-157 — relevant for any competitive athlete.
⌑ III · Reported ProtocolsWhat users actually do.
The following describes patterns reported in the literature on BPC-157 use in animal models and case reports — it is NOT a prescription, recommendation, or endorsement. BPC-157 is not approved by the FDA for any therapeutic use in humans.
Common reported dose
200-500 mcg subcutaneously, 1-2 times daily, either near the site of injury (proximal SC) or at a remote site (abdominal SC). Animal studies have used both routes with similar reported efficacy.
Reported duration
Most reported protocols run 4-8 weeks for soft-tissue injury contexts. Animal evidence does not support a clear duration ceiling; human safety data for chronic use is absent.
Oral formulation
Stable to gastric acid in some animal studies (the compound was originally derived from gastric juice), but human oral bioavailability is not well characterized. Most "research" use is parenteral.
Cycling
Some users report 4 weeks on, 2 weeks off as a conservative approach. No clinical data supports a specific cycling regimen.
⌑ IV · Quality and SourcingWhat you cannot verify.
BPC-157 is sold by dozens of "research peptide" suppliers, none of which are FDA-regulated. Products vary widely in:
- Purity — independent testing has found peptide content ranging from 60-95% of the labeled amount
- Sterility — sterile peptide injection requires aseptic compounding; many products are not produced under such conditions
- Identity — some products labeled BPC-157 contain different peptides or contaminants when tested
- Reconstitution instructions — bacteriostatic water vs. sterile water vs. saline affects shelf life and safety
Compounding pharmacies operating within state pharmacy regulations have historically provided one quality-controlled source, but the FDA's 2023 designation of BPC-157 as ineligible for outsourcing facility compounding (FDA 503B list) has restricted that pathway. Current sourcing is overwhelmingly through unregulated channels.[5]
⌑ V · ConsiderationsWhat to be aware of.
- Cancer risk. Theoretical concern: BPC-157 upregulates VEGF (angiogenesis) and growth factor signaling, both pathways involved in tumor biology. No human evidence of increased cancer incidence, but no evidence of safety either. Patients with active or recent cancer should not use.
- Anti-doping status. BPC-157 is included on the World Anti-Doping Agency (WADA) Prohibited List under S0 (non-approved substances). Any competitive athlete subject to drug testing must not use.
- Injection site reactions. Reported in animal studies and anecdotally in humans. Local pain, redness, and minor inflammation typical with subcutaneous peptide administration.
- Regulatory status (changing). The FDA has signaled increasing scrutiny of peptide compounding. Legal availability through research peptide channels remains a gray area subject to enforcement.
⌑ VI · The Codex VerdictWhat this entry says.
BPC-157 has impressive preclinical credentials and a plausible mechanistic story. It also has, after three decades, essentially no human clinical trial evidence to support the injury-recovery claims made about it in the wellness market. The compound is sold by unregulated suppliers with unverifiable quality. The user is taking on real epistemic risk.
This Codex documents what is known. The current state of evidence does not justify the certainty with which BPC-157 is often marketed. Anyone considering use should: (1) understand that this is investigational, (2) source from the highest-quality available supplier they can verify, (3) inform their physician, and (4) recognize the absence of long-term safety data.